The KLC1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model providing a polyclonal knockout cell population derived from the human NCI-H1975 non-small cell lung adenocarcinoma cell line. This product consists of a pool of cells harboring targeted disruptions in the KLC1 locus, generated without clonal isolation, enabling loss-of-function studies in a heterogeneous yet well-characterized genetic background.
NCI-H1975 is an epithelial cell line isolated from a lung adenocarcinoma patient and carries the epidermal growth factor receptor (EGFR) mutations L858R and T790M. The L858R mutation confers sensitivity to first-generation EGFR tyrosine kinase inhibitors, while the T790M gatekeeper mutation is a primary cause of acquired resistance. Consequently, NCI-H1975 cells are extensively used in cancer research to investigate mechanisms of drug resistance and to screen next-generation therapeutic agents.
KLC1 encodes kinesin light chain 1, an adaptor subunit of the kinesin-1 motor complex that partners with the motor subunit KIF5B to mediate anterograde transport of diverse cargoes along microtubules. KLC1 directly interacts with cargo adaptors such as JIP1 and JIP3, linking the motor to mitochondria, lysosomes, and signaling endosomes. This transport is tightly regulated by upstream kinases including GSK3??, JNK, and AMPK, which phosphorylate KLC1 to modulate cargo binding. Consequently, KLC1 is a central node in pathways governing mitochondrial distribution, lysosomal positioning, NF-??B activation, and Wnt/??-catenin signaling.
Disruption of KLC1 in the NCI-H1975 background is predicted to impair kinesin-1-dependent intracellular trafficking, leading to altered mitochondrial dynamics, lysosomal mobility, and spatial control of signaling complexes. In these EGFR-mutant, drug-resistant cells, loss of KLC1 may diminish NF-??B-mediated survival signaling and attenuate tumor cell migration, processes that are often co-opted during acquired resistance. Thus, this knockout model provides a platform to dissect how microtubule-based transport contributes to cancer cell adaptation and drug tolerance.
Researchers can use this polyclonal knockout population to study kinesin-dependent trafficking in lung adenocarcinoma, organelle dynamics via live-cell imaging of mitochondria and lysosomes, and signaling impacts by western blotting for KLC1, KIF5B, and NF-??B components. Further assays include wound-healing migration, cell viability under EGFR inhibitor treatment, and RNA-seq for pathway analysis. The model also validates KLC1 as a target and bridges cancer and neurodegenerative research. For further technical information, please contact Ascent Research.
